Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trialRenske CF Hebing, Marry Lin, Maja Bulatovic Calasan, Ittai B Muller, Sohaila Mahmoud, Sandra Heil, Eduard A Struys, Bart JF van den Bemt, Jos WR Twisk, Willem Lems, Michael T Nurmohamed, Gerrit Jansen, Robert de Jonge
21 December 2022
Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritisLotte van Ouwerkerk, Maarten Boers, Paul Emery, Pascal HP de Jong, Robert BM Landewé, Willem Lems, Josef S Smolen, Patrick Verschueren, Tom WJ Huizinga, Cornelia F Allaart, Sytske Anne Bergstra
16 December 2022
Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smokingBowen Tang, Qianwen Liu, Anna Ilar, Pernilla Wiebert, Sara Hägg, Leonid Padyukov, Lars Klareskog, Lars Alfredsson, Xia Jiang
6 December 2022
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trialJeffrey R Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L Bhatt, Levent M Gunay, Naonobu Sugiyama, Carol A Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranic, Juan J Gómez-Reino
5 December 2022
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritisDaniel H Solomon, Jon T Giles, Katherine P Liao, Paul M Ridker, Pamela M Rist, Robert J Glynn, Rachel Broderick, Fengxin Lu, Meredith T Murray, Kathleen Vanni, Leah M Santacroce, Shady Abohashem, Philip M Robson, Zahi Fayad, Venkatesh Mani
See the full list of authors30 November 2022
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritisAndreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimme L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja A Stamm
See the full list of authors3 January 2023
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III studyEugen Feist, Saeed Fatenejad, Sergey Grishin, Elena Korneva, Michael E Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen, Roy M Fleischmann
10 November 2022
Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritisMingyue Cheng, Yan Zhao, Yazhou Cui, Chaofang Zhong, Yuguo Zha, Shufeng Li, Guangxiang Cao, Mian Li, Lei Zhang, Kang Ning, Jinxiang Han
10 November 2022
PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytesJiajie Tu, Weile Chen, Yilong Fang, Dafei Han, Yizhao Chen, Haifeng Jiang, Xuewen Tan, Zhen Xu, Xuming Wu, Huihui Wang, Xiangling Zhu, Wenming Hong, Zhenbao Li, Chen Zhu, Xinming Wang
See the full list of authors23 January 2023
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trialAndra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L Bhatt, Carol A Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B Shapiro, Janet E Pope, Hendrik Schulze-Koops
12 October 2022